PURPOSE: To investigate the functional and oncologic outcomes of @entity1 with locally advanced or lymph node (LN) @entity263 (PCa) treated by laparoscopic radical prostatectomy (LRP) with extended lymph node dissection (ePLND). METHODS: From June 2004 to March 2014, a total of 232 cases (pT3-4N0-1M0) including 160 locally advanced PCa and 72 LN metastatic PCa who received immediate @entity342 deprivation therapy after LRP plus ePLND were enrolled onto our study. The @entity1 were followed up for 12 to 124 months. Surgical records, surgical margin status, complications, urinary continence, and oncologic outcomes were presented. RESULTS: The mean operation time and @entity548 were 230 minutes and 105 mL, respectively. The rates of urinary continence were 91.4% and 94.8% at 6 and 12 months, respectively. We observed 122 biochemical recurrent cases. The 5- and 8-year biochemical relapse-free survival rates were 47.3% and 46.7%, respectively. The 5- and 8-year overall and @entity5 -specific survivals were 81.2%, 80.1%, 90.6%, and 90.6%, respectively. The survival analysis showed that biochemical recurrence-free survival rates were significantly lower for @entity1 with higher Gleason score (77.3% vs. 39.6% vs. 30.8%, P  = .003 log rank), higher T stage (55.7% vs. 41.4% vs. 21.4%, P  = .039 log rank), positive surgical margin (51.1% vs. 29.3%, P  = .000 log rank), and higher CAPRA-S score (68.6% vs. 35.0% vs. 29.2%, P  = .000 log rank). There were no significant differences in biochemical relapse-free (40.9% vs. 49.3%, P  = .286), overall (75.6% vs. 81.9%, P  = .398), and @entity5 -specific (87.3% vs. 92.1%, P  = .284) survival between LN-positive and -negative PCa. CONCLUSION: LRP plus ePLND in combination with immediate @entity342 deprivation therapy is a feasible approach to @entity1 with pT3-4N0-1M0 PCa; favorable functional and oncologic outcomes were presented postoperatively.

Laparoscopic Radical Prostatectomy Plus Extended Lymph Node Dissection in Combination With Immediate @entity342 Deprivation Therapy for Cases of pT3-4N0-1M0 XXXX : A Multimodal Study of 8 Years' Follow-up.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['metastatic prostate cancer'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen']
@entity263 :: (MESH:D011471,Disease) :: ['Prostate Cancer']
